Fig. 2: Effects of Chidamide on DLBCL cells.

a Comparison differences of HDAC1-10 mRNA expression between DLBCL tissues and normal B cells (top). Data were obtained from GEO database (GSE12453). IC₅₀s of Chidamide against recombinant human HDACs (bottom). b Five DLBCL cell lines were treated with 0.01, 0.1, 1, 10, 100 µM of Chidamide or DMSO for 24 h and percentages of cell death were determined by the MTT test. (top) Data shown are mean ± SD from three independent experiments. IC₅₀s and IC₉₀s of DLBCL cell lines to the treatment of Chidamide were calculated with the linear regression based on MTT data (bottom). c Effect of different dose of Chidamide on PARP-1 cleavage, Histone-H3 acetylation and expression of Histone-H3. DLBCL cell lines, OCI-Ly7 and Su-DHL8, were treated with indicated dose of Chidamide for 24 h, the levels of FL-PARP-1 and C-PARP-1, ac-Histone-H3 (Lys27) and Histone-H3 expression were determined by western blotting. Numbers under each lane were ratios of specific protein to β-actin. d Time-course of Chidamide on Histone-H3 acetylation and expression of Histone-H3. DLBCL cell lines, OCI-Ly7, Su-DHL6 and Su-DHL8 were treated with 5 µM Chidamide for indicated hours, the levels of ac-Histone-H3 (Lys27) and Histone-H3 expression were determined by western blotting. Numbers under each lane were ratios of specific protein to β-actin. Data presented were from at least three independent experiments.